BioAge Labs, Inc. ( (BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented to its investors.

Citi analyst Samantha Semenkow initiated coverage of BioAge Labs (BIOA) with a Buy rating and $45 price target BioAge is a clinical-staged ...

Obesity-drug developer BioAge Labs Inc. held on to a slim gain at the closing bell and natural-gas producer BKV Corp. ended flat Thursday, the day the two initial public offerings debuted.

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human ...

Earlier this week, BioAge said in a filing it was looking to offer 10.5M shares priced between $17 and $19 per share.The ...

A well-known collaborator with Eli Lilly – BioAge Labs is focusing on developing an anti-obesity drug for the elderly "by targeting the biology of human ageing", the biopharmaceutical start-up said.

Kristen Fortney, cofounder and CEO of BioAge Labs. From the San Francisco Business Times. BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs ...

Texas-based Barnett Shale driller BKV Inc. priced below the estimated range, while obesity-drug developer BioAge Labs Inc. priced midrange ahead of their first day of trading on Thursday.

The popularity of the Chandigarh chair, created by a team led by Swiss architect Pierre Jeanneret, has shone a light on the erasure of local designers in the mid-century modern design narrative.

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge’s lead ...

RICHMOND, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases ...